AstraZeneca scraps plan to expand vaccine plant in the UK in blow to government

Associated Press Finance
02-01

LONDON (AP) — Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new Labour government for diluting the financial support that had been offered by the previous Conservative administration.

In a blow to Treasury chief Rachel Reeves at the end of a week when she trumpeted the government's plans to bolster British economic growth and make the country more attractive to international investors, AstraZeneca said it will no longer expand its facility in Speke, near Liverpool.

“Several factors have influenced this decision including the timing and reduction of the final offer compared to the previous government’s proposal," a company spokesperson said.

The existing facility will continue to operate and no jobs are at risk.

The government said a “change in the make-up of the investment” proposed by AstraZeneca, which is headquartered in Cambridge, England, had led to a change in the grant it was willing to offer.

Details of what had changed were not immediately available.

The previous government said the investment would have given the U.K.’s life sciences sector a boost as well as improving public health protection and pandemic preparedness.

AstraZeneca became particularly prominent during the coronavirus pandemic, when it partnered with Oxford University to create one of the vaccines.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10